Two new investors lead funding round as company looks to accelerate commercial rollout in key US market as well as Europe and Australia
Mainstay Medical
Funding will drive commercialisation of Reactiv8 in critical US market
Group eyeing up to 10 investments, mostly in therapeutics and medical device sectors
Company secures FDA approval for its flagship medical device called ReActiv8
Mainstay Medical’s flagship product is now eligible for reimbursement from private health funds
Mainstay Medical cites poor liquidity in shares and cost for decision to take business private
Revenue at Irish medical device company targeting chronic back pain almost doubles
Holiday week sees thin trading in Dublin as rise in online shopping boosts Amazon
‘Day 100’ meeting reviews status of application’s review
Company submits application for pre-market approval to US regulator
Group beats €100m target and intends to invest the bulk of the fund in Europe and US
Company insists other data support case for its implanted electrical stimulation device
Company awaits data as it looks to roll-out ReActive8 device to patients in the US
Call for Government action after funding falls 9% to €453m in first six months of 2018
YOU MAY ALSO LIKE...
How does a post-Brexit world shape the identity and relationship of these islands
Inquests into the nightclub fire that led to the deaths of 48 people
Weddings, Births, Deaths and other family notices